Abstract
Two pharmaceutical giants—Pfizer and Novartis—are following opposite paths in generics. Last week, Pfizer agreed to shed its Italian generic drug marketing company, Dorom, by selling the unit to Israel's Teva Pharmaceutical Industries for $85 million. This acquisition is consistent with our leadership strategy in the generic marketplace, says Israel Makov, CEO of Teva, which bills itself as among the largest generic drug companies in the world. The deal leaves Pfizer with almost no more business in generics. Novartis is taking the opposite tack, busily building up its generics business as part of its Sandoz subsidiary. Sandoz has completed the acquisition of Sabex Holdings, the Canadian generics manufacturer, for $565 million, a deal that was first announced in June. The acquisition of Sabex, which had sales of nearly $90 million in its most recent fiscal year, establishes a presence for Sandoz in Canada and gives Sandoz a big boost in ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
